Welcome Reception

Breakfast & Registration 

Welcome & introduction
Gareth Morgan & Ola Landgren 

Session 1A: Genomics and epigenomics 2026
Chairs: Gareth Morgan and Leif Bergsagel

Are NSD2 or MAF targets for therapy

• Mechanistic basis of NSD2 as an oncogene: Yubao Wang
• Apoptotic profiling of t(4:14) MM: Lawrence Boise
• Distinct epigenetic programs of high-risk MM subtypes create targetable dependencies: Benjamin Barwick

Panel Discussion                                                                                                                   

Session 1B: Can we identify new prognostic factors and targets for therapy?        
Chairs: Gareth Morgan and Leif Bergsagel

• Genetics and epigenetics of early myeloma: Mehmet Samur
• Structural variation in HR: Patrick Blaney
• Targeting structural variation by their detailed characterization: Brian Walker
• Deciphering the biology of bone marrow-independent disease to identify therapeutic vulnerabilities:
  Niels Weinhold

Panel Discussion                                                                                                                   

Break

Session 2: Targeting resistance mechanisms and HR biology
Chairs: Marta Chesi &  Larry Boise 

• Epigenetic and epitranscriptomic targets in MM: Felipe Prosper
• Epi drivers and drug resistance: Gareth Morgan
• Targeting super enhancers: Leif Bergsagel
• How to overcome resistance mechanisms to bispecific antibodies in MM: Nizar Bahlis
• Targeting p300: Charlotte Pawlyn

Panel discussion

Lunch

Session 3: Using biological models and single cell analyses to study drugs
Chairs: Felipe Prosper & Brian Walker

• Modelling resistance to t-cell therapies: Marta Chesi
• Using mouse models to find new targets: Marta Larrayoz
• A novel, genetically driven vulnerability to mitosis targeting in multiple myeloma: Sarah Gooding
• CSF-1R inhibition & lenalidomide synergy in myeloma post ASCT: Simone Minnie
• Immune landscape–driven target discovery in myeloma: Manoj Bhasin

Panel discussion: Future strategies for myeloma management

Plenary Lecture
Location, Location, Location; expanding our understanding of the TME in myeloma: Robert Orlowski
Chairs:  Ola Landgren & Gareth Morgan

Panel discussion

Break

Session 4: Integration of Clinical and Translational Research with the MMRF
Chairs: George Mulligan & Hearn Cho

• Molecular correlates of dara use in RRMM: TBC
• MM immune atlas: insights on NDMM and RRMM: Chuck Acharya
• Horizon 2: an adaptive platform trial for high-risk NDMM: Ben Derman

Panel Discussion

Closing Remarks for Day 1

Attendee Dinner

Welcome and Introductions Day 2

Session 5: Early use of immunotherapy in multiple myeloma
Chairs: Faith Davies & Madhav Dhodapkar

• Use of cell-free DNA (cfDNA) to monitor antigen escape and detect early relapsing disease: Paola Neri
• Anito-cel: Ciara Freeman
• High-risk in the context TecDara: Mark Raab
• The role of abbreviated bispecific immuno-consolidation in newly diagnosed myeloma; IMMUNOPLANT Study: Dickran Kazandjian
• Cartitude-4: update: Yi Lin
• Isatuximab combinations: Dickran Kazandjian
• Alpha Emitter Targeted Therapy: Damian Green

Panel Discussion

Session 6: Artificial intelligence in multiple myeloma
Chairs: Ciara Freeman & Leo Rasche                                                                         

• The benefit of AI in multiple myeloma: Ciara Freeman
• AI in patient management: Ola Landgren

Panel discussion: Optimizing therapy choices at relapse

Break

Session 7: Optimizing T-Cell Engaging therapy
Part 1: CAR-T Management
Chairs: Adam Cohen & TBC

• Managing neurotox and ALC expansion: Leo Rasche
• The role of arlocel: Marc Raab
• STEM study: Adam Cohen
• In vivo CAR-T designs: Yi Lin
• The role of anti CD19 binders in CAR-T constructs: Nina Shah

Panel discussion: Optimizing the use of CAR-T in the clinic

Lunch

Part 2: Bispecifics, ADCs, and Allogeneic CAR-T therapies in MM
Chairs: Yi Lin & Malin Hutlcrantz

• Tal/Tec and their management: Malin Hultcrantz
• Linvoseltamab; Hans Lee
• Elranatamab: Ola Landgren
• Cevostamab:  Adam Cohen
• CB-011: Binod Dhakal
• ABBV 383: Shaji Kumar
• Trispecifics: Faith Davis
• AbbVie’s multiple myeloma vision: Annelore Cortoos

Panel discussion: Optimizing the use of Bispecifics  & ADCs in the clinic 

Summary & closing remarks of iwMyeloma 2026

Gareth Morgan & Ola Landgren

iwMyeloma Scientific Committee: 

Gareth Morgan (Co-Chair) USA, Ola Landgren (Co-Chair) USA
Leif Bergsagel USA, Lawrence Boise USA, Ciara Freeman USA, Charlotte Pawlyn UK,
Leo Rasche Germany, Niels Weinhold Germany

Emeritus Scientific Committee
Ken Anderson USA, Irene Ghobrial USA, Sagar Lonial USA, Maria Victoria Mateos Spain,
Jesus San Miguel Spain, Pieter Sonneveld NL, Keith Stewart Canada